Inhibikase Therapeutics Inc (IKT) — Financial Flexibility Index
Inhibikase Therapeutics Inc (IKT) has a Financial Flexibility Index of -1.51x as of September 2025. Free cash flow of $-10.14 Million (operating CF $-10.59 Million minus capex $452.02K) represents -2% of total liabilities ($6.70 Million). Check Inhibikase Therapeutics Inc (IKT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Inhibikase Therapeutics Inc Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Inhibikase Therapeutics Inc across 9 annual periods. See IKT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Inhibikase Therapeutics Inc (2016–2024)
Year-by-year free cash flow to debt coverage for Inhibikase Therapeutics Inc. For the full company profile including market capitalisation, see market cap of Inhibikase Therapeutics Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -5.13x | $-19.15 Million | $-19.15 Million | $3.73 Million | ▼ -0.1% |
| 2023 | -5.12x | $-18.07 Million | $-18.09 Million | $3.53 Million | ▼ -16.8% |
| 2022 | -4.39x | $-17.11 Million | $-17.35 Million | $3.90 Million | ▼ -24.4% |
| 2021 | -3.53x | $-14.30 Million | $-14.30 Million | $4.05 Million | ▼ -1460.7% |
| 2020 | -0.23x | $-1.13 Million | $-1.13 Million | $5.00 Million | ▼ -202.4% |
| 2019 | -0.07x | $-338.29K | $-338.29K | $4.53 Million | ▼ -137.9% |
| 2018 | 0.20x | $714.99K | $714.99K | $3.62 Million | ▲ +369.4% |
| 2017 | -0.07x | $-126.39K | $-126.39K | $1.73 Million | ▼ -275.0% |
| 2016 | -0.02x | $-29.57K | $-29.57K | $1.51 Million | — |